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ShiveringAbstract Background: Shivering is one of the most stressful complications for both the surgeon
and the anesthesiologist during neuraxial anesthesia. The aim of this prospective randomized dou-
ble blinded study was to evaluate the effectiveness of preoperative administration of granisetron,
dexmedetomidine, and tramadol in prevention of shivering in patients undergoing elective opera-
tions with subarachnoid anesthesia.
Methods: 320 patients ASA I or II aged between 18 and 65 years scheduled for elective operations
under subarachnoid block were included in the study. They were divided randomly into four equal
groups, and 10 min before performance of subarachnoid block, patients in group G (n= 80)
received 40 lg/kg intravenous infusion of granisetron in 100 ml of normal saline, patients in group
D (n= 80) received 0.5 lg/kg intravenous infusion of dexmedetomidine in 100 ml of normal saline,
patients in group T (n= 80) received 1 mg/kg intravenous infusion of tramadol in 100 ml of normal
saline, and patients in group C (n= 80) received 100 ml of normal saline as control.
The following parameters were assessed: heart rate, mean arterial blood pressure, SPo2 and core
temperature at the following times: 0 time, 5 min,10 min, 15 min, then every 15 min till end of
the surgery. The incidence and intensity of shivering during the operation were recorded.
Results: Study found statistically significant decrease in the incidence of shivering in group G,
group D, and group T in comparison with group C without statistical significant difference between
group G, group D, and group T. There was no statistical significant difference in the core temper-
ature between the four groups.
Conclusion: Preoperative administration of granisetron, dexmedetomidine, and tramadol was
effective in decreasing the incidence and intensity of post subarachnoid shivering without increasing
the incidence of the side effects.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
196 A.Z.E. Mohamed1. Introduction
Shivering is a fasciculation or tremors of the face, jaw, head,
trunk, or extremities lasting longer than 15 s [1]. Multiple
sequelae caused by shivering were increase in oxygen consump-
tion, carbon dioxide production, metabolic rate up to 400%,
and lactic acidosis [2]. Shivering usually associates anesthesia
either general or subarachnoid anesthesia [3]. Multiple mecha-
nisms are suggested to explain occurrence of shivering such as
inhibition of central thermoregulation [4] or inhibition of the
autonomic vasoconstrictive tone in the lower half of the body
after subarachnoid anesthesia leading to redistribution of core
temperature to the peripheral tissues and then to the environ-
ment leading to hypothermia [5]. Researches continue to find
the best anti-shivering drug but still the optimum one is not
discovered yet [6].
Granisetron is serotonin (5-hydroxytyptamine 3,5-HT)
antagonist which is used mainly as anti-emetic but recently it
has been reported that it can prevent post anesthetic shivering
as serotonin (5-hydroxytyptamine 3,5-HT3) is involved in the
regulation of body temperature as it is responsible for adjust-
ment of thermoregulatory set range in the anterior hypothala-
mus [7] so administration of 5-HT3 antagonists would
decrease the set range and prevent post anesthetic shivering [8].
Dexmedetomidine is an a 2-agonist that decreases vaso-
constriction and shivering thresholds and when administered
with meperidine additively can reduce the shivering threshold
in healthy volunteers. Intraoperative dexmedetomidine reduces
postanesthetic shivering as the meperidine does after surgery
[9].
Tramadol, which is a weak opioid, has a role in prevention
of post subarachnoid shivering as it inhibits reuptake of nor
epinephrine, dopamine, and serotonin [10].
Hypothesis of this study was that each of granisetron, tra-
madol, and dexmedetomidine when administered intra-
venously before the subarachnoid block could decrease the
incidence and severity of post subarachnoid shivering.
This prospective randomized controlled double blinded
study aimed to evaluate the effectiveness of granisetron,
dexmedetomidine, and tramadol in decreasing the incidence
and severity of the post subarachnoid block shivering and their
effect on the core temperature of the patients during
anesthesia.
2. Methods
This study was done in El Minia University Hospital in the
period from January to December 2013, after approval of
the local ethical committee from the faculty of medicine in
El-Minia University and obtaining written informed consents
from the patients. 320 patients, ASA I or II aged 18–65 years
prepared for elective operations under subarachnoid anesthe-
sia, were included in this study. Patients with coagulopathy,
impaired renal or hepatic function, thyroid disease, alcohol
intake, use of vasodilators, and patients with fever more than
37.5 C, and those who are allergic to any of the used drugs are
excluded from the study.
This was a prospective randomized study, and patients eli-
gible for the study (320 patients) were randomly allocated into
the four study groups as 80 patients per group using random
allocation software (windows software, version 1.0, may2004). The allocation ratio is 1:1, and the group identification
paper was put in a sealed and opaque envelops to hide alloca-
tion and it was opened just before the patients entered the
study.
This was a double blind study in which the drugs of the
study were administered preoperatively in 100 ml of normal
saline by an anesthesiologist not involved in the study, and
the bottles are labeled as G, D, T, and C and given to the
blinded patients via intravenous route 5 min before perfor-
mance of subarachnoid anesthesia. All the members of anes-
thetic team, surgeons, and patients were blinded with the
type of the test drug. At the end of the study these labels were
known as follows:
Group (G) received 40 lg/kg granisetron.
Group (D) received 0.5 lg/kg dexmedetomidine.
Group (T) received 1 mg/kg tramadol.
Group (C) received only 100 ml normal saline.
Temperature of the operating room was maintained at
22–24 C and measured by wall thermometer. Intravenous flu-
ids were used at room temperature and no other warming
devices were used. No premedications were given to the
patients. Monitor was used to record heart rate, noninvasive
blood pressure, and SPo2 of the patients. Core temperature
probe was introduced in the ear until touching tympanic mem-
brane and covered with cotton swap. Advisor monitors (Smith
Medical PM, Inc., Wakkesha, WL 53186) were used in this
study. These parameters were measured immediately after the
subarachnoid block considered 0 time, and then at 5, 10,
15 min and then every 15 min till the end of the surgery. Under
complete aseptic conditions subarachnoid anesthesia was per-
formed at L4–5 through midline approach with 25 gauge spinal
needle while the patients were in the sitting position using
15 mg of hyperbaric bupivacaine hydrochloride after keeping
at room temperature for 15 min. Patients were repositioned
supine with oxygen 4 l/min was applied via nasal cannula.
Patients were covered with one surgical drape. Motor block
was assessed with modified Bromage scale after 5 min of sub-
arachnoid anesthesia (0 = no block 1 = hip block 2 = hip
and knee block 3 = hip, knee, and ankle block). Sensory block
was evaluated by pin prick sensation. Shivering was assessed by
5 point scale (0 = no shivering, 1 = piloerection, peripheral
vasoconstriction, peripheral cyanosis or combination with no
other cause, without visible muscular activity, 2 = visible mus-
cular activity confined to one muscle group, 3 = muscular
activity in more than one muscle group, 4 = gross muscular
activity involving the entire body) [11]. Intravenous meperidine
(10–25 mg) was given if patients had shivering (grade 3 or 4) not
controlled by the test drugs and the total dose was recorded for
each group. Atropine 0.5 mg intravenous was given if there was
bradycardia less than 50 beat per minute. Ephedrine 10 mg
intravenous was given if the blood pressure decreased less than
20% of the baseline measurement. Side effects of the drugs such
as nausea, vomiting, hypotension, excessive sedation, respira-
tory depression (SPo2 less than 90%) are recorded. At the
end of the operation the patients are transferred to the Post
Anesthesia Care Unit (PACU) covered with one cotton
blanket.
The primary outcome was the incidence and severity of post
subarachnoid block shivering, while the 2nd outcome was the
core temperature of the patients.
Prevention of post subarachnoid block shivering 1972.1. Statistical analysis
Sample size was calculated by PASS 2000 (Power Analysis
Software; NCSS, Kaysville, UT, USA) and it was determined
on the base that the incidence of shivering was 55% and could
be reduced to 30% with effective treatment, with alpha error of
0.05, power of 80%. It was calculated to be 72 patients and it
was increased to 80 patients for dropout and more accuracy.
SPSS software, version 17 (SPSS Inc., Chicago, IL, USA)
was used to analyze the statistical data. Results are expressed
as mean ± SD or numbers. Categorical data including inci-
dence of shivering were analyzed using Chi square test.
Numerical data as core temperature were analyzed using Stu-
dent’s T-test between two groups, while independent T-test
was used to compare data within the same group, and between
the 4 groups was done by one-way ANOVA test. P
value < 0.05 was considered significant.
3. Results
This study included 320 patients who were divided into four
groups of 80 patients for each flowchart Fig. 1. There was
no significant difference between the 4 groups as regards age,
weight, height, gender, type of operations, and duration of
surgery.
There was no significant difference between the 4 groups as
regards vital signs (SPo2, HR, B.P) when compared to each
other.
There was a statistically significant decrease in the core tem-
perature after the subarachnoid anesthesia in the 4 groups
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Figure 1 Flowchaanesthesia but there was no statistical significant difference
between the 4 groups when compared to each other at different
points Fig. 2.
The incidence of shivering (Fig. 3) was in 44 (55%) patients
in the control group (n= 80) who developed shivering: only 2
patients developed grade 4 shivering, 7 patients developed
grade 3 shivering, 20 patients developed grade 2, and 15
patients developed grade 1 while 36 didn’t develop shivering
at all. In granisetron group 11 (13.75%) patients developed dif-
ferent grades of shivering, no patient developed grade 4 or 3
shivering, 6 patients developed grade 2 shivering, 5 patients
developed grade 1 shivering, while 69 patients developed no
shivering. In dexmedetomidine group 9 (11.25%) patients
developed different grades of shivering as follows, no patients
developed grade 3 or 4, 4 patients developed grade 2 shivering,
5 patients developed grade 1 shivering while 71 patients devel-
oped no shivering. In tramadol group 10 (12.5%) developed
different grades of shivering as follows, no patients developed
grade 3 or 4 shivering, 5 patients developed grade 2 shivering, 5
patients developed grade 1 shivering while 70 patients devel-
oped no shivering.
As regards side effects only 1 patient in control group and
tramadol group developed nausea and vomiting. 7 patients in
each group of granisetron group, dexmedetomidine group, and
control group while 8 patients in tramadol group developed
hypotension which was treated with ephedrine intravenously.
As regards total dose of meperidine was given to each
group for treating shivering which was not controlled by the
study drugs and there was a significant increase in its dose in
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Figure 2 Core temperature in different groups. Significant
decrease in core temperature in the 4 groups after subarachnoid
block compared to the baseline measurement. No significant



















Figure 3 Shivering grades in different study groups. ̽p< 0.05
compare control group with the other 3 groups.
Table 1 Demographic data, type, and duration of surgery.
Item Granisetron (n= 80) Dexmedetomidin
Age (years) 44 ± 13 years 42 ± 14 years
Weight (kg) 84 ± 12 85 ± 10 kg
Height (cm) 172 ± 8 cm 173 ± 9 cm
Sex (male/female) 49/31 40/40









*p value < 0.05 considered significant.
One-way ANOVA test used to compare between numerical data.
Chi-square test used for categorical data.
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Shivering represents a body response to the decreased body
temperature which should be maintained within the range of
36.5–37.5 C [12]. Multiple risk factors such as age, high level
of the sensory block, and temperature of the operation room
and fluids are contributing to shivering in neuraxial anesthesia
[13].
Different drugs have been used in prevention and treatment
of shivering such as meperidine, clonidine, and ketamine but
these drugs still have many drawbacks limiting their use as
hypotension with clonidine, tachycardia and hypertension with
ketamine [14]. The best drug for prevention of shivering is the
one which can reduce the temperature threshold for shivering
near the patient’s body temperature with fewer side effects [15].
Although the room temperature was maintained in this study
within 22–24 C and the fluids given to the patients were at
room temperature keeping body temperature of the patients
within its normal range was not applicable and also shivering
could be observed in patients with normal temperature under
neuraxial anesthesia [16].
The current study showed that each of granisetron
40 lg/kg, dexmedetomidine 0.5 lg/kg and tramadol 1 mg/kg,
decreased the incidence and intensity of shivering in patients
exposed to elective operations under subarachnoid anesthesia
when compared to placebo, but these drugs couldn’t prevent
the significant decrease in the core temperature after the sub-
arachnoid block. This anti-shivering effect was not associated
with increase in the side effects.
Kose et al. [17] examined effectiveness of prophylactic
intravenous administration of 0.25/kg mg and 0.5 mg/kg of
ketamine in cesarean section under spinal anesthesia and they
found that the incidence of shivering in control group was 40%
which is lower than what was noticed in the control group of
this study (55%). This difference may be caused by additional
warming measures such as warming of the fluids and forced-
warm air that maintained body temperature of the patients.
Incidence of shivering in the control group in the prospec-
tive randomized study by Powell and Buggy [18] to evaluate
the efficacy of ondansetron and dolasetron which are serotonine (n= 80) Tramadol (n= 80) Control (n= 80) P value
42 ± 14 years 45 ± 12 years 0.985
87 ± 8 kg 83 ± 12 kg 0.945
172 ± 7 cm 172 ± 8 cm 0.707
46/34 48/32 0.835








Table 2 Side effects in each study group.
Item Granisetron (n= 80) Dexmedetomidine (n= 80) Tramadol (n= 80) Control (n= 80) P value
Nausea, vomiting 0 0 1 1 0.52
Respiratory depression 0 0 0 0 1
Hypotension 7 7 8 7 0.74
Bradycardia 0 0 0 1 0.54
Excessive sedation 0 0 0 0 1
One-way ANOVA test was used to analyze number of side effects occurred.
No significant difference between the 4 groups.
Table 3 Total dose of drugs administered to all patients (80 patients) in each study group.
Item Granisetron (n= 80) Dexmedetomidine (n= 80) Tramadol (n= 80) Control (n= 80) P value
Atropine 0 0 0 1 mg 0.65
Ephedrine 100 mg 105 mg 110 mg 110 mg 0.86
Metoclopramide 0 0 15 mg 10 mg 0.52
Meperidine 80 mg 60 mg 80 mg 450 mg* 0.03
One-way AOVA test used for analysis of data between the 4 groups.
* p value < 0.05 considered significant.
Prevention of post subarachnoid block shivering 199antagonist in prevention of shivering in patients under spinal
anesthesia was 55% which was in agreement with the present
study, and they found that serotonin antagonist (ondansetron
and dolasetron) decreases this incidence to 33%. Granisetron
is more potent than ondansetron.
These findings was in agreement with the prospective ran-
domized double blinded study by Sajedi et al. [19] to evaluate
the efficacy of prophylactic administration of 40 lg/kg of gran-
isetron in comparison with tramadol 0.1 mg/kg and meperi-
dine 0.4 mg/kg in elective orthopedic surgeries under general
anesthesia and they found that granisetron, and tramadol were
effective as meperidine in prevention of shivering without pro-
longing the emergence time from anesthesia.
Usta et al. [20] in their study on 60 patients scheduled for
minor elective surgeries under spinal anesthesia to evaluate
the effectiveness of 1 lg/kg dexmedetomidine infusion as a
loading dose followed by 0.4 lg/kg/hr during surgery in pre-
vention of shivering when compared to placebo group and
they found that dexmedetomidine decreases the incidence of
shivering from 57% in the control group to 10% but this effect
was associated with increased sedation which was caused with
the high dose used.
This study found that there was a statistically significant
decrease in the core temperature in the four groups after the
subarachnoid block when compared to the baseline value but
without significant difference in between the four groups.
This is in agreement with Bozgeyik et al. [21], who com-
pared between dexmedetomidine 0.5 lg/kg and tramadol
1 mg/kg in 100 ml of normal saline against placebo after spinal
anesthesia in prevention of shivering in patients that under-
went knee arthroscopy and they found that in spite of the effi-
ciency of dexmedetomidine and tramadol in decreasing the
incidence of shivering they cannot prevent occurrence of
hypothermia. Talke et al. [22] suggested that dexmedetomidine
action in prevention of shivering is related to its ability to
increase the range of temperature that did not stimulate thethermoregulatory defense mechanism and can decrease shiver-
ing threshold temperature.
Elvan et al. [23] who found that dexmedetomidine 1 lg/kg
followed by 0.4 lg/kg infusion could reduce the incidence of
shivering in 90 female patients did hysterectomy and they
found that the core temperature decreased in the patients after
anesthesia.
Bicer et al. [24] compared dexmedetomidine 1 lg/kg with
0.5 mg/kg meperidine in 120 patients under general anesthesia
exposed for major abdominal or orthopedic surgeries for
1–3 h and they found that dexmedetomidine could reduce
the incidence of shivering but it was associated with delayed
orientation time which may be related to the dose 1 lg/kg
they used which is double the dose that I have been used
0.5 lg/kg.
The incidence of excessive sedation, respiratory depression,
nausea and vomiting in this study was low in spite of using
dexmedetomidine and tramadol may be related to the low dose
used 0.5 lg/kg dexmedetomidine and 1 mg/kg of tramadol and
slow infusion rate.
There are some limitations to this study, first is the wide
variation of surgeries included in the study with different size
of the area exposed for surgery, different volume of irrigating
and washing fluids in urological operations. Second limitation
is not using nasopharyngeal probe (more accurate) for core
temperature measurement but it was not suitable for awake
not sedated patients. Third limitation is the duration of
included surgeries which was around 95 min; lengthy opera-
tions should be investigated to know the later effects of these
drugs.
5. Conclusion
Preoperative administration of granisetron, dexmedetomidine,
and tramadol in small dose and slow infusion rates was effec-
tive in decreasing the incidence and intensity of shivering in
200 A.Z.E. Mohamedpatients that underwent surgeries under subarachnoid anesthe-
sia without increase in the incidence of the side effects.
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